Drug Trial Radar · NCT05799469
Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer
Last checked: Nov 19, 2026Latest source record: Apr 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
May 1, 2023
Primary completion
May 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Chongqing University Cancer HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, single-center, exploratory study, the purpose of this study is to evaluate the efficacy and safety of envafolimab combined with Chemoradiotherapy in participants with locally advanced cervical cancer.
Conditions
- Locally Advanced Cervical Cancer
Interventions
EnvafolimabDrug
SC
CisplatinDrug
IV infusion
External Beam Radiotherapy (EBRT)Radiation
45-50.4Gy
Brachytherapy (BT)Radiation
Performed according to clinically required dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) at Month 24 as Assessed by the InvestigatorTime frame: The cut-off date is event-driven and estimated to be approximately 48 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chongqing university Cancer Hospital
Chongqing, CHN, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.